Reference Database

Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion.
Bogers, Willy M
Oostermeijer, Herman
Mooij, Petra
Koopman, Gerrit
Verschoor, Ernst J
Davis, David
Ulmer, Jeffrey B
Brito, Luis A
Cu, Yen
Banerjee, Kaustuv
Otten, Gillis R
Burke, Brian
Dey, Antu
Heeney, Jonathan L
Shen, Xiaoying
Tomaras, Georgia D
Labranche, Celia
Montefiori, David C
Liao, Hua-Xin
Haynes, Barton
Geall, Andrew J
Barnett, Susan W
The Journal of infectious diseases 2015 Mar 15;211: 947-55

Self-amplifying messenger RNA (mRNA) of positive-strand RNA viruses are effective vectors for in situ expression of vaccine antigens and have potential as a new vaccine technology platform well suited for global health applications. The SAM vaccine platform is based on a synthetic, self-amplifying mRNA delivered by a nonviral delivery system. The safety and immunogenicity of an HIV SAM vaccine encoding a clade C envelope glycoprotein formulated with a cationic nanoemulsion (CNE) delivery system was evaluated in rhesus macaques. The HIV SAM vaccine induced potent cellular immune responses that were greater in magnitude than those induced by self-amplifying mRNA packaged in a viral replicon particle (VRP) or by a recombinant HIV envelope protein formulated with MF59 adjuvant, anti-envelope binding (including anti-V1V2), and neutralizing antibody responses that exceeded those induced by the VRP vaccine. These studies provide the first evidence in nonhuman primates that HIV vaccination with a relatively low dose (50 µg) of formulated self-amplifying mRNA is safe and immunogenic.

Forward to a friend